Why the study?
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
Population
100 patients with dilated cardiomyopathy (DCM), mean age 47.7 years, mean NYHA class 2.17, mean LVEF 27.3%
Comparison
Trimetazidine 20 mg three times daily (tid) vs Conventional therapy
Design
RCT, randomized
Follow-up
6 months
Authors
Loading...
Supports adjunctive trimetazidine in dilated cardiomyopathy; extends metabolic modulation evidence in systolic HF.
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
Trimetazidine added to conventional therapy significantly improves left ventricular function, functional capacity, and BNP levels in patients with dilated cardiomyopathy.
Jatain et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: